LENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume on Analyst Upgrade
LENZ Therapeutics (NASDAQ:LENZ) experienced a surge in trading volume after Raymond James Financial upgraded its price target from $39.00 to $40.00, maintaining an outperform rating. The stock traded 415,673 shares, a 73% increase from the previous session. Other brokerages, including HC Wainwright and Citigroup, also raised their price targets, with consensus ratings indicating a buy. The stock's market cap is $848.16 million, and it reported a quarterly EPS of ($0.53), beating estimates. LENZ focuses on developing therapies for vision improvement, with products in Phase III trials.
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) saw strong trading volume on Friday after Raymond James Financial raised their price target on the stock from $39.00 to $40.00. Raymond James Financial currently has an outperform rating on the stock. 415,673 shares were traded during trading, an increase of 73% from the previous session's volume of 239,685 shares.The stock last traded at $30.08 and had previously closed at $29.77.
A number of other brokerages also recently commented on LENZ. HC Wainwright reiterated a "buy" rating and issued a $48.00 price objective (up previously from $38.00) on shares of LENZ Therapeutics in a research report on Monday. Citigroup reissued a "buy" rating and issued a $49.00 target price (up from $45.00) on shares of LENZ Therapeutics in a report on Thursday. Finally, Piper Sandler initiated coverage on LENZ Therapeutics in a report on Monday, April 14th. They issued an "overweight" rating and a $51.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $49.60.
Get LENZ Therapeutics alerts:
View Our Latest Research Report on LENZ Therapeutics
Institutional Investors Weigh In On LENZ Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new stake in LENZ Therapeutics during the 4th quarter valued at $46,000. Tower Research Capital LLC TRC increased its holdings in LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after purchasing an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in LENZ Therapeutics in the 4th quarter valued at $67,000. Banque Transatlantique SA bought a new position in LENZ Therapeutics in the 1st quarter valued at $119,000. Finally, GAMMA Investing LLC boosted its position in LENZ Therapeutics by 5,254.1% in the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after buying an additional 5,727 shares during the last quarter. 54.32% of the stock is owned by institutional investors and hedge funds.
LENZ Therapeutics Stock Performance
The stock has a market capitalization of $848.16 million, a P/E ratio of -15.92 and a beta of 0.42. The stock has a 50-day simple moving average of $30.99 and a 200 day simple moving average of $26.90.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.05. The firm had revenue of $5.00 million during the quarter, compared to the consensus estimate of $5.00 million. Equities analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.
About LENZ Therapeutics
(Get Free Report)LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Articles
- Five stocks we like better than LENZ Therapeutics
- About the Markup Calculator
- Rocket Lab Reports Next Week: Here’s What Investors Should Know
- Compound Interest and Why It Matters When Investing
- Apple Stock: Big Earnings, Small Move—Time to Buy?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Amazon's Earnings: What Comes Next and How to Play It
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in LENZ Therapeutics Right Now?
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
